NO20043644L - Torre granulerte formuleringer av azitromycin - Google Patents

Torre granulerte formuleringer av azitromycin

Info

Publication number
NO20043644L
NO20043644L NO20043644A NO20043644A NO20043644L NO 20043644 L NO20043644 L NO 20043644L NO 20043644 A NO20043644 A NO 20043644A NO 20043644 A NO20043644 A NO 20043644A NO 20043644 L NO20043644 L NO 20043644L
Authority
NO
Norway
Prior art keywords
azithromycin
dry granulated
granulated formulations
formulations
dry
Prior art date
Application number
NO20043644A
Other languages
English (en)
Inventor
Barbara Alice Johnson
Ernest Shing Quan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20043644L publication Critical patent/NO20043644L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043644A 2002-02-01 2004-08-31 Torre granulerte formuleringer av azitromycin NO20043644L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35404102P 2002-02-01 2002-02-01
PCT/IB2003/000212 WO2003063838A1 (en) 2002-02-01 2003-01-20 Dry granulated formulations of azithromycin

Publications (1)

Publication Number Publication Date
NO20043644L true NO20043644L (no) 2004-09-21

Family

ID=27663280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043644A NO20043644L (no) 2002-02-01 2004-08-31 Torre granulerte formuleringer av azitromycin

Country Status (18)

Country Link
US (1) US7438924B2 (no)
EP (1) EP1478347A1 (no)
JP (1) JP2005526020A (no)
KR (1) KR100676025B1 (no)
CN (1) CN1646104A (no)
AR (1) AR038371A1 (no)
AU (1) AU2003201146B2 (no)
BR (1) BR0307331A (no)
CA (1) CA2474809A1 (no)
CO (1) CO5611118A2 (no)
MX (1) MXPA04007427A (no)
NO (1) NO20043644L (no)
NZ (1) NZ534234A (no)
PL (1) PL372394A1 (no)
RU (1) RU2283092C2 (no)
TW (1) TW200306865A (no)
WO (1) WO2003063838A1 (no)
ZA (1) ZA200405805B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
EP2422775A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
JP3444874B1 (ja) * 2002-12-02 2003-09-08 高砂香料工業株式会社 顆粒状香料およびその製造方法
EP1648472A2 (en) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stable oral compositions of azithromycin monohydrate
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0417360A (pt) 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2006067576A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
CA2611114C (en) * 2005-06-08 2014-09-23 Orion Corporation An entacapone-containing oral dosage form
IN2014MN00380A (no) 2006-06-30 2015-06-19 Iceutica Pty Ltd
US8808751B2 (en) * 2006-06-30 2014-08-19 Iceutica Pty Ltd. Methods for the preparation of biologically active compounds in nanoparticulate form
MX2009004557A (es) * 2006-10-27 2009-05-11 Janssen Pharmaceutica Nv Composicion farmaceutica granulada seca y metodos para producirla.
US8951562B2 (en) * 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20070521L (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
JP5292105B2 (ja) * 2007-01-11 2013-09-18 株式会社カネカ 補酵素ｑ１０粒子の製造方法
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
SI3326620T1 (sl) 2010-12-16 2020-07-31 Novo Nordisk A/S Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline
JP5585920B2 (ja) * 2010-12-27 2014-09-10 富田製薬株式会社 粒子状製剤
JP6022538B2 (ja) 2011-04-12 2016-11-09 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104203221A (zh) 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
UA27040C2 (uk) * 1987-07-09 2000-02-28 Пфайзер Інк. Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
TW271400B (no) * 1992-07-30 1996-03-01 Pfizer
US5795871A (en) 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
RU2130311C1 (ru) * 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
JP2001515865A (ja) 1997-09-10 2001-09-25 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての９ａ−アザライド
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
JP2002531409A (ja) * 1998-11-30 2002-09-24 テバ ファーマシューティカル インダストリーズ リミティド アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
EE200300575A (et) 2001-05-22 2004-04-15 Pfizer Products Inc. Asitromütsiini kristalsed vormid
HUP0402291A2 (hu) * 2001-10-18 2005-03-29 Teva Pharmaceutical Industries Ltd. Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
MXPA04007427A (es) 2004-10-11
NZ534234A (en) 2007-05-31
CA2474809A1 (en) 2003-08-07
CN1646104A (zh) 2005-07-27
AR038371A1 (es) 2005-01-12
US20030228357A1 (en) 2003-12-11
AU2003201146B2 (en) 2008-04-17
ZA200405805B (en) 2006-05-31
JP2005526020A (ja) 2005-09-02
BR0307331A (pt) 2004-12-07
RU2004123624A (ru) 2005-04-10
EP1478347A1 (en) 2004-11-24
TW200306865A (en) 2003-12-01
US7438924B2 (en) 2008-10-21
WO2003063838A1 (en) 2003-08-07
CO5611118A2 (es) 2006-02-28
KR20040079954A (ko) 2004-09-16
RU2283092C2 (ru) 2006-09-10
PL372394A1 (en) 2005-07-25
KR100676025B1 (ko) 2007-01-29

Similar Documents

Publication Publication Date Title
NO20043644L (no) Torre granulerte formuleringer av azitromycin
NO20043110L (no) Direkte komprimerbare formuleringer av azitromycin
FI20021262A0 (fi) Sokerien kiteytys
DK1689360T3 (da) Tørpulverformuleringer
DK1531673T3 (da) Hidtil ukendt 2-pyridylethylbenzamidderivat
NO20054260D0 (no) Disepergebar formulering av en anti-inflammatorisk forbindelse
DE60331470D1 (de) Av-system
NO20053115D0 (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
NO20052335D0 (no) Dispergerbare defracirox-tabletter
EE200300575A (et) Asitromütsiini kristalsed vormid
FR2838446B1 (fr) Melanges de stabilisants
DE60322651D1 (de) Trockentoner
DE60327057D1 (de) Luftkissenboot
NO20044916L (no) Preparater av sulfinylacetamid
NO20043418L (no) Stabiliserte adenovirusformuleringer
SE0302837L (sv) Användning av IR-kamera
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
EP1531795A4 (en) FORMULATIONS LIMITING THE EXTENSION OF PULMONARY INFECTIONS
DE60329761D1 (de) Calcium-aufnahme verstärker
IS7500A (is) thurrdufts samsetningar
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
PT1393641E (pt) Entretela fixante
FI20021578A (fi) Paperin karakterisointi
ATE382264T1 (de) Trockenhefe-komposition

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application